"Tetrahydroisoquinolines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A group of ISOQUINOLINES in which the nitrogen containing ring is protonated. They derive from the non-enzymatic Pictet-Spengler condensation of CATECHOLAMINES with ALDEHYDES.
| Descriptor ID |
D044005
|
| MeSH Number(s) |
D03.633.100.531.820
|
| Concept/Terms |
Tetrahydroisoquinolines- Tetrahydroisoquinolines
- Tetrahydro-Isoquinolines
- Tetrahydro Isoquinolines
- 1,2,3,4-Tetrahydroisoquinolines
|
Below are MeSH descriptors whose meaning is more general than "Tetrahydroisoquinolines".
Below are MeSH descriptors whose meaning is more specific than "Tetrahydroisoquinolines".
This graph shows the total number of publications written about "Tetrahydroisoquinolines" by people in this website by year, and whether "Tetrahydroisoquinolines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2007 | 1 | 0 | 1 |
| 2011 | 1 | 0 | 1 |
| 2012 | 0 | 1 | 1 |
| 2013 | 2 | 0 | 2 |
| 2015 | 2 | 0 | 2 |
| 2017 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Tetrahydroisoquinolines" by people in Profiles.
-
Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy: Subgroup analysis of a phase 3, randomized clinical trial. Gynecol Oncol. 2017 09; 146(3):531-537.
-
Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial. J Clin Oncol. 2016 Mar 10; 34(8):786-93.
-
Redefining the standard of care in metastatic leiomyosarcoma. Lancet Oncol. 2015 Apr; 16(4):360-2.
-
A Phase II multicenter, open-label, clinical and pharmokinetic trial of PM00104 in patients with advanced Ewing Family of Tumors. Invest New Drugs. 2014 Feb; 32(1):171-7.
-
Clinical benefit of trabectedin in uterine adenosarcoma. Med Oncol. 2013 Jun; 30(2):501.
-
Role of palliative chemotherapy in advanced epithelioid sarcoma. Am J Clin Oncol. 2012 Aug; 35(4):351-7.
-
Trabectedin in advanced uterine leiomyosarcomas: a retrospective case series analysis from two reference centers. Gynecol Oncol. 2011 Dec; 123(3):553-6.
-
Docetaxel plus trabectedin appears active in recurrent or persistent ovarian and primary peritoneal cancer after up to three prior regimens: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol. 2011 Mar; 120(3):459-63.
-
Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol. 2007 Jul; 8(7):595-602.